Vision 2030 procurement has changed who buys, and SFDA licensing decides who is even eligible to carry your product. Our job here is finding and qualifying that distributor: the candidate universe built from licence records, the classes each firm genuinely holds confirmed, any representation already committed in your device group flagged, and a shortlist you can act on with the evidence attached.
Saudi Arabia is around sixty per cent of Gulf healthcare expenditure, and the 2026 budget put health and social development at some two hundred and fifty-nine billion riyals, close to a fifth of total spending. But the number that should shape a distribution plan is a channel split rather than a budget line. On the official statistics for 2024, government still holds the beds — around fifty-seven per cent of the eighty-two thousand total — while private providers now take about forty-two per cent of roughly a hundred and seventy million outpatient encounters, up from thirty-eight per cent in 2020.
So there are two businesses here, not one. The tender business runs through the national unified procurement company, which serves several hundred public hospitals and primary care centres, and accounted for something in the order of two fifths of pharmaceutical volume on 2021 data, with one listed local manufacturer putting tenders at over half the market. The retail business runs through private chain pharmacies, of which there were nearly eleven thousand in 2024, and through the national electronic prescription service.
Supply is still mostly foreign. Industry analysis has put roughly three quarters of pharmaceutical sales with foreign companies against about a quarter for the twenty-odd domestic manufacturers, while locally produced medicines met about thirty-six per cent of consumption in 2021, up from thirty per cent in 2018. The transformation programme targets at least forty per cent domestic production by 2030, and for insulin specifically a ninety per cent local supply target.
For devices the import dependence is sharper still — close to nine tenths of need met by imports, mainly from the United States and Europe. Published device market sizes differ by a factor of three between credible sources depending on what they count, so this page does not quote one. What is not in doubt is the direction: a privatisation pipeline covering hundreds of hospitals and thousands of primary care centres, and a target to lift the private sector to around two thirds of provision by 2030.
There is no published list of SFDA-licensed healthcare distributors you can work from, and a commercial directory will not tell you the thing that matters. SFDA licenses establishments through its GHAD portal and classifies them A to D, and the licence a company holds decides which device classes it may lawfully import and store. A distributor can be real, well known, well capitalised and still unable to carry your product.
The harder problem is that the wrong appointment can close the market rather than merely cost you a year of it. A foreign manufacturer’s device authorisation is issued in the manufacturer’s own name and reaches the market through a licensed Authorised Representative — and SFDA permits only one of those per device class or general device group, with a separate licence for each manufacturer represented. A candidate already acting as AR in your group is not a hard negotiation; it is structurally unavailable. An AR whose appointment ends also stays responsible for the devices it covered until a replacement is in place, which is why an orderly exit is something to design at the start.
The commercial channel is concentrated. The best available analysis put the top ten pharmaceutical distributors at roughly eighty-five per cent of the market and described consolidation as extreme, with the largest single player above eleven per cent and one group representing around twenty-five manufacturers while reaching ninety-nine per cent of retail pharmacies. That analysis dates from November 2021 and we have found nothing current to confirm or revise it, so treat the numbers as vintage and the shape as probably still right.
The licensed tail, by contrast, is long and growing. The regulator reported over nine thousand licensed factories and warehouses in 2025, up almost a fifth on the year, including well over five hundred warehouses in the drug sector and more than thirteen hundred in medical devices. The honest picture is a licensed population in the high hundreds to low thousands with value concentrated in about ten groups. Getting onto the register is cheap. Getting into the hospital and tender channel is not.
Vertical integration into retail is real and documented. One listed group runs close to a thousand retail pharmacies and also owns a pharmaceutical and consumer goods distribution business with a hundred-and-thirty-thousand square metre central hub, nine regional warehouses and several thousand trade accounts. Another chain operates over eleven hundred pharmacies in the Kingdom and states coverage of ninety-seven per cent of the population. One counterparty can therefore be both your wholesaler and your largest retail customer.
Whether to look national or Gulf-wide splits by product type. Pharmaceutical distribution here is predominantly national, with the larger houses describing themselves as suppliers to the Saudi market. Device and diagnostics distribution has genuine regional groups — one runs its own operations in five Gulf states with around two hundred principals and six distribution centres. But the regulatory relationship is always single-country, because the authorised representative must be a Saudi legal entity even where the commercial partner is regional.
The Saudi stack has a commercial layer, a regulatory layer and — if government revenue is the point — a procurement layer that most brand owners discover late.
Two of these are about your own structure rather than the candidate’s, and they come first because getting them wrong makes the rest academic.
Since January 2024, multinationals without a Saudi regional headquarters are effectively shut out of government tenders above a million riyals unless a narrow exemption applies, and exemptions are sought by the government entity in advance rather than granted automatically. Either build the headquarters or ensure the Saudi distributor signs.
An economic evaluation study has been mandatory for human pharmaceuticals since July 2025, against a stated cost-effectiveness threshold, and prices are referenced against a basket of around fifteen countries. The first generic is capped at seventy per cent of originator, the second sixty-five, later entrants sixty. A price you did not plan for breaks the distributor’s economics after signature.
A recurring disqualification pattern is a registration that does not cover the specific model offered, or that expires during the framework period. Ask for the certificate per item, read the model numbers against your own part numbers, and read the expiry date against the tender term.
Where those three are different or unclear entities, bids fail. Establish who holds the authorisation, whose name the registration sits in, and who will actually submit — then issue a tender-specific letter that names them correctly.
Sales and marketing roles moved to sixty per cent Saudisation for establishments with three or more workers, announced in January 2026 and effective three months later, with procurement at seventy per cent. A field organisation is a sales organisation, so this lands on the function you are buying. Ask for their compliance position and their hiring plan.
There were over fourteen hundred products on that list across sixteen sectors, with the authority planning expansion toward two thousand and pharmaceuticals named as a focus. Non-compliance with a mandatory listing excludes a bid at technical evaluation, which is before anyone looks at your price.
Competing foreign products are evaluated as though priced ten per cent higher than bid, and minimum local content requirements began phasing in from August 2026 with further tranches annually. A price that wins on a spreadsheet can lose on the evaluation.
There is no statutory termination compensation regime, but damages claims are available and courts may weigh the relationship’s length and the distributor’s market investment. Deregistration from the agencies register may require the outgoing party’s cooperation, and the registration can outlive the contract. Put notice, data handover and registration transfer in the original agreement.
This is the strongest citation available anywhere in this material. The regulator’s own anticipated drug shortage list carries marketing authorisation holder or agent change as one of four recognised shortage reasons, alongside commercial issues, global shortage and regulatory issues. Switching distributor is formally classified as a cause of supply interruption.
A brand assumes its Saudi distributor is the contracting party, and finds the tender documents require the multinational to demonstrate headquarters compliance, an exemption, or that it is out of scope. Contracts not exceeding a million riyals are exempt; most worth winning are not.
The ten per cent notional uplift on foreign bids, plus exclusion risk for failing applicable requirements and referral to a committee that can bar a contractor from government contracting altogether. A new government tenders law was approved in August 2026 and its effect on the framework is not yet clear.
Published inspection data shows the majority of manufacturing inspections carried out at foreign sites, with hundreds of major and dozens of critical deficiencies recorded in single years and manufacturers suspended. Your plant, not your distributor, is often the point of failure.
Published review times for new medicines ran at around a hundred and ninety days in 2011, over three hundred by 2016, and back near a hundred and twenty by 2021. Planning around a current headline figure is planning around a good year. For devices, only the lowest risk class has a printed statutory review period at all.
Research published in 2026 found prescription patients reporting recurring out-of-stock situations and having to visit several pharmacies to fill a prescription, attributing broader shortages to weak early notification, thin margins on essential medicines and limited enforcement. Your brand carries that experience.
You need a Saudi legal entity as your authorised representative, and an establishment-licensed importer to clear and store goods — though they need not be the same company, and official export guidance states foreign exporters are not required to appoint an agent or distributor. A registered commercial agency under the Commercial Agencies Law must be Saudi-owned; alternatively you can hold your own licensed Saudi entity, subject to conditions including operations in at least three countries.
Usually that is the only practical route. Since January 2024, multinationals without a Saudi regional headquarters are effectively barred from government tenders above a million riyals unless a narrow exemption applies, so who signs matters more than whose brand it is. The distributor additionally needs vendor registration with the national procurement company, registration on the government tendering platform, your tender-specific authorisation letter and an establishment licence.
Not necessarily. Since July 2025 an economic evaluation study has been mandatory for human pharmaceuticals at registration, price re-evaluation and renewal, against a stated cost-effectiveness threshold per quality-adjusted life year. Prices are also referenced against a basket of around fifteen countries, and generics are capped at seventy per cent of originator for the first entrant, sixty-five for the second and sixty thereafter. Model the price before the margin.
For devices the regulator permits only one authorised representative per device class or general group, so the regulatory answer is one per group. Commercially, analysis from 2021 put the top ten pharmaceutical distributors at roughly eighty-five per cent of the market, which means breadth comes from choosing the right one rather than from appointing several. Regional groups exist in devices and diagnostics, but the Saudi registration still sits in a Saudi entity.
For a product with no Saudi registration, plan nine to twelve months, and three to five for a complete file. The lowest device risk class has a printed review period of thirty-five working days; higher classes have no printed statutory timeline. Published review times for new medicines have swung between about a hundred and twenty and over three hundred days across the last fifteen years, so a single headline figure is not safe for planning.
Harder than it looks. There is no statutory termination compensation regime, but damages claims under the Civil Transactions Law are available and courts may weigh the relationship’s duration and the distributor’s investment in the market. Deregistration from the agencies register may require the outgoing party’s cooperation, and the registration can persist after the contract ends. The regulator lists agent change as a recognised cause of anticipated shortage, so expect a gap and write the handover terms into the original contract.
Most of what goes wrong here is settled before a shortlist exists: who signs the tender, what your registered price turns out to be, and whether the field organisation you are buying can staff itself. Tell us what you are trying to place and we will come back on all three.
How we verify How a distributor search runs